GO
| HSI1 | 24,175.12 | +144.94 | 339.59B |
| HSCEI1 | 8,039.19 | +41.90 | 95.13B |
| Back Zoom + Zoom - Block Traded | |
|
2026-07-10 13:46:22 Nomura published a report stating that growth in the market for GLP-1 receptor agonists (GLP-1 RAs) in the rest of the world (ROW) will drive significant expansion of the drug category. The global GLP-1 RAs market is currently valued at USD72 billion. According to third-party forecasts, the market size is expected to reach USD180 billion over the next decade, representing a CAGR of about 11%. In terms of geographic expansion, the extension from the highly profitable US market to ROW markets with lower pricing but large patient populations will become a major market driver. The broker noted that molecules under development feature greater safety, longer-lasting efficacy and fewer side effects, while indications are expanding beyond diabetes and obesity. The commercial success of GLP-1 RAs lies in their efficacy, enabling expansion from diabetes treatment into chronic weight management. Nomura raised the TP for WUXI APPTEC (02359.HK) from HKD157.07 to HKD180.22, while maintaining a Buy rating; raised the TP for INNOVENT BIO (01801.HK) from HKD114.64 to HKD123.17, while maintaining a Buy rating; and raised the TP for ASYMCHEM (06821.HK) from HKD115.43 to HKD131.48, while maintaining a Buy rating. (su/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |